mice, in parallel with 1.4 t O.l-and 1.9 iz 0.5-fold increments in duodenal RNA and protein content, respectively (P < 0.05-0.001).
Similarly, the activities of duodenal maltase, sucrase, lactase, glutamyl transpeptidase, and dipeptidyl-peptidase IV (215 t 28% of controls; P < 0.001) were increased by GLP-2. Oral or duodenal administration of glucose or maltose did not reveal any differences in the ability of GLP-2-treated mice to absorb these nutrients, possibly because of decreases in expression of the glucose transporters sodium-dependent glucose transporter-l (SGLT-I) and GLUT-2. In contrast, absorption of leucine plus triolein was increased after duodenal administration in GLP-2-treated mice (P < 0.01-0.001).
Finally, GLP-2 did not alter other markers of intestinal or pancreatic gene expression, including levels of mRNA transcripts for ornithine decarboxylase, multidrug resistance gene, amylase, proglucagon, proinsulin, and prosomatostatin. Thus induction of intestinal growth by GLP-2 in wild-type mice results in a normal-toincreased capacity for nutrient digestion and absorption in vivo.
intestinal growth; intestinal enzymes; nutrient digestion; nutrient absorption THE PROGLUCAGON GENE is expressed in both the pancreatic A and intestinal L cells (12, 26). Tissue-specific posttranslational processing of proglucagon'by the prohormone convertases gives rise to different proglucagonderived peptides (PGDPs) in each tissue (8, 26). The most notable of the pancreatic PGDPs is glucagon, whereas the L cell produces several structurally related peptides, including the glucagon-like peptides GLP-1 and GLP-2, as well as glicentin and oxyntomodulin, which contain glucagon in their sequence. The function of GLP-1 as a glucose-dependent insulinotropic factor, as well as an enterogastrone, has been well established (27, 43) . However, the physiological actions of the other intestinal PGDPs, and of GLP-2 in particular, have remained unclear. A role for the intestinal PGDPs in bowel growth was strongly suggested by studies in two patients who were found to have PGDP-producing tumors in association with small intestinal villous hyperplasia and hypertrophy (1, 36) . A large number of studies using experimental models of adaptation have subsequently provided correlative evidence for a relationship between increased production of the PGDPs and growth of the small intestine (2, 32, 39). We have very recently identified the intestinal PGDP GLP-2 as a potent stimulator of growth in the small intestine of mice (9). Treatment with 6.25-43.75 lug GLP-2 twice daily for 10 days leads to a 1.5 to 2-fold increase in small intestinal wet weight, predominantly due to a significant increment in villous height. Although the histological appearance of the small intestine is normal in GLP-2-treated mice, it remains to be established whether the newly grown small intestine is capable of normal physiological functions. These analyses are particularly important in view of a report by Lund et al. (24) suggesting that GLP-2 may stimulate differentiation rather than growth of intestinal epithelial IEC-6 cells in vitro. The results of the present study demonstrate that the growth-enhanced small intestines of GLP-2-treated mice have a normal-to-increased digestive capacity, likely due to increased activity of the brush-border enzymes.
METHODS
Six-week-old female CD1 mice (Charles River Canada, St. Constant, QC, Canada) were injected twice daily with synthetic rat GLP-2 (2.5 pg SC) in phosphate-buffered saline (PBS) or with vehicle alone (PBS) for 8-10 days. Mice were then fasted overnight, and the small intestine was removed, rinsed with saline, and weighed. Duodenal sections (the first 5 cm) were collected for analysis of enzyme activities. Additional 5-to lo-cm segments from the duodenum, jejunum, ileum, colon, and pancreas were also collected for peptide and/or mRNA transcript analyses. All animal protocols were approved under Canadian Council of Animal Care Guidelines.
In vitro enzyme assays. Duodenal samples from vehicleand GLP-2-treated mice were homogenized in 2.4 ml of sodium phosphate buffer, pH 7.0, at 4°C and stored at -70°C before analysis. Protein content was determined by the Lowry protein assay (22 after which the stomach and duodenum were exposed through a midline incision. D-Glucose (0.75 mg/g), maltose (1.13 mg/g>, or a mixture of L3H]leucine (2.6 X IO6 dpmmouse) and [14C]triolein (1.7 X lo6 dpm/ mouse) was then injected into the lumen of the duodenum by use of a 30-gauge needle, and the tissues were returned to the abdominal cavity. Blood samples were collected and analyzed as described for the oral nutrient tolerance tests.
Peptide analysis. Duodenal and ileal sections, as well as colon and pancreas, from vehicle-and GLP-2-treated mice were homogenized twice in 5 ml of extraction medium [l N HCl, 5% (vol/vol) formic acid, 1% (vol/vol) trifluoroacetic acid, and 1% (wt/vol) NaCl], as described in detail previously (11). Peptides and small proteins were collected by passage through a C18 Sep-Pak (Waters Associates, Milford, MA) and were stored at -70°C before analysis. PGDP content was determined in two separate radioimmunoassays (RIAs): 1) glucagon-like immunoreactivity (GLI) was detected using antiserum K4023 (BiosPacific, Emeryville, CA), which is directed toward the midsequence of glucagon and recognizes glicentin, oxyntomodulin, and glucagon (8, 11), and 2) GLP-2 was detected using antiserum UTTH-7, which cross-reacts with the COOH-terminal end of GLP-2 and recognizes native GLP-2, as well as the pancreatic major proglucagon fragment in which the NH2-terminal end of GLP-2 is linked to GLP-I through an intervening peptide (unpublished data). Immunoreactive insulin (IRI) levels were determined by RIA with a kit from Linco Research (St. Charles, MO); protein content in the extracted samples was measured by the Lowry protein assay (22).
Data analysis. Three to ten mice were analyzed per group in each experiment. Statistical differences were determined by analysis of variance with n-l post hoc custom hypotheses tests, using an SAS program (Statistical Analysis Systems, Cary NC) for IBM computers.
RESULTS
The wet weight of the small intestine was significantly increased after twice daily administration of 2.5 lug GLP-2 for 10 days, to 136 ? 2% of vehicle controls (n = 28-32; P < 0.001). This was paralleled by a 1.4 t O.l-fold increase in the duodenal RNA content (P < 0.05). Body weight was not significantly different between vehicle-and GLP-2-treated animals ( Fig. 1) .
Treatment of mice with GLP-2 for 10 days induced a significant increase in the activities of all of the brushborder enzymes tested, when expressed as units of enzyme per 5 cm of duodenum (as percent control: maltase, 189 t 62; sucrase, 193 2 44; lactase, 274 ? 103; y-GGT, 204 _ + 660 and DPP IV, 214 t 66; Fig. 2 ). Taken together, there'was an overall increase in the enzyme activities of the duodenum in GLP-2-treated mice, rising to 215 t 28% of controls (P < 0.001). These changes occurred concomitantly with a similar increase in the total protein content of the duodenal segment, to 187 t 54% of controls. Thus, when the 'data were normalized for the increased protein content (U enzyme activity per g of protein), no significant differences could be detected between vehicle-and GLP-Ztreated mice for any Analysis of total of the enzymes jejunal RNA assayed. from vehicle-and GLP-Z-treated mice demonstrated that transcript levels for the luminal and basolateral facilitative glucose transporters (SGLT-1 and GLUT-Z, respectively) were decreased in GLP-Z-treated mice (Fig. 3A) . Transcript levels in ileum were variable for SGLT-1 but were also reduced for GLUT-Z. No marked changes were seen in either jejunum or ileum for expression of ODC, an enzyme involved in epithelial cell turnover (23). However, transcript levels for MDR, a marker of small bowel epithelium (14), were decreased in jejunum. Analysis of 18s RNA levels confirmed that loading of RNA onto each lane of the gel was equal. The results of densitometric scans of the blots are shown in Fig. 3C .
To assess the capacity of the intact intestine to digest a disaccharide, as well as to absorb glucose, oral glucose and maltose tolerance tests were conducted in conscious mice. Administration of either glucose or maltose was associated with a prompt rise in blood glucose levels, peaking at 20-30 min, followed by a slow fall toward basal levels over the subsequent 90 min (Fig. 4) . No differences were seen between the glycemic profiles obtained for vehicle-and GLP-Z-treated mice, although maltose administration was associated with a slightly faster rise in glycemia in mice receiving GLP-2 (P < 0.01 at t = 10 min). To assess the ability of the bowel to absorb amino acids, as well as to digest triglycerides and absorb the resultant fatty acids, similar studies were carried out using a mixture of ["H]leucine and [14C]triolein. G as t ric gavage with this mixture resulted in a slow rise in plasma 3H levels, reaching a plateau at t = 60 min. I n contrast, plasma 14C counts peaked at 45 min and then fell toward basal level over the ensuing 145 min. GLP-2 treatment did not significantly change the plasma profiles obtained in response to the oral leucine-triolein mixture.
GLP-1 is a known inhibitor of gastric emptying (43), a major determinant in the rate of flow of nutrients into the duodenum. To control for the possibility that GLP-2 treatment also affects transit from the stomach to the duodenum, we next studied the absorption of nutrients administered directly into the duodenum. The glycemic profiles obtained after duodenal administration of glucose or maltose were not different between vehicle-and GLP-Z-treated mice (Fig. 5) . In contrast, greater increments in the plasma levels of 3H and 14C were observed in GLP-Z-treated mice (P < 0.01-0.001).
We also studied the effects of a single acute dose of GLP-2 on luminal nutrient absorption, because the results of a recent study suggested that intravenous infusion of GLP-2 rapidly increases the rate of epitheha1 cell basolateral D-ghCOSe transport (5). Fasted mice were given a single subcutaneous injection of saline or GLP-2 (2.5 pg), followed by a duodenal glucose tolerance test 2 h later. No differences in glycemic profiles were detected between vehicle-and GLP-Z-treated mice (Fig. 6) .
We have previously observed that mice with PGDPexpressing tumors exhibit not only small bowel growth but also decreased expression of the intestinal and pancreatic PGDPs (10, 11). It is not known, however, whether chronic administration of GLP-2 alone has any effect on production of the endogenous PGDPs by proglucagon-expressing L or A cells. Therefore, sections of duodenum, ileum, colon, and pancreas were examined for their levels of the endogenous PGDPs by use of RIAs for both GLI and GLP-2 (Fig. 7) . As anticipated from the known distribution of L cells in the mouse intestine (12), GLI and GLP-2 levels were lowest in duodenum and highest in colon. GLP-2 treatment did not affect the concentrations of the PDGPs in any of the tissues examined. Examination of the levels of proglucagon mRNA transcripts in intestine and pancreas similarly revealed a lack of effect of GLP-2 treatment on the L and A cell, respectively (Fig. 3) . These observa-DISCUSSION tions suggest that GLP-2 administration is not associated with inhibition of endogenous proglucagon gene Treatment of mice for 10 days with 2.5 pug GLP-2 expression in vivo. As an additional indicator of pancretwice daily resulted in a 36% increase in small bowel atic gene expression, immunoreactive insulin concentrawet weight. This change is consistent with the results tions (Fig. 7) and mRNA transcript levels for proinsuof a previous study, in which 15 to 2-fold increments in lin, amylase (Fig. 3, B and C) and prosomatostatin (not murine small intestinal weight were observed after 10 shown) were also assessed and found to be normal after days of treatment with higher concentrations of GLP-2 10 days of GLP-2 administration.
(9). Although increased nutrient intake by itself can Consistent with the observed increase in intestinal weight, both total protein and total RNA were also increased in the duodenum of GLP-2-treated mice. Morphological analyses have demonstrated that GLP-2 increases intestinal villous height through stimulation of crypt cell proliferation but has no effect on crypt depth or muscle thickness (9). Thus the results of the present study confirm the previous report of the intestinal growth-enhancing properties of GLP-2 and extend these findings by the analysis of macromolecule expression and enzymatic function in the small bowel of GLP-2-treated mice. The activities of the brush-border disaccharidases and peptidases determined for control mouse duodenum were comparable to those reported by others (6, 13,28). Interestingly, the twofold increment in enzyme activity observed in GLP-2-treated mice occurred in parallel with intestinal growth; hence the increased mucosal epithelium induced by GLP-2-treatment exhibited normal enzyme concentrations.
Similar to the effects of GLP-2 administration alone, intestinal growth after massive small bowel resection is associated with up to 110% increases in the activities of maltase, sucrase, and lactase in young rats (44). It must be noted, however, that increased dietary substrate loading can lead to induction of maltase, sucrase, DPP IV, and r-GGT, but not of lactase, in mouse intestine (6,13, 34). Similarly, the activities of maltase, sucrase, lactase, and DPP IV in human intestine are markedly decreased by total parenteral nutrition and are restored by refeeding (15). However, the GLP-2-induced increase in enzyme activity occurred in the absence of changes in nutrient intake (Brubaker and Drucker, unpublished data), suggesting a direct effect of GLP-2 on the intestinal mucosa. The mechanisms whereby the effects of GLP-2 are exerted are not known, because the GLP-2 receptor has not yet been identified.
Nonetheless, the effects of GLP-2 appear to be relatively specific for intestinal enzymes, as pancreatic amylase levels were not affected.
GLP-2 is not the only growth factor known to stimulate small intestinal growth. Elevation of growth hormone levels in transgenic mice leads to intestinal hyperplasia in association with enhanced production of insulin-like growth factor I (IGF-I) in the intestine (41). Interestingly, although duodenal sucrase activity is increased in the transgenic mice, lactase levels remain normal. Treatment with IGF-I alone, however, does not affect the activity of any of the duodenal disaccharidases (42). Furthermore, systemic administration of cortisol, a steroid hormone important for intestinal stimulate growth of the small intestine, including GLP-2, the effects of each factor on intestinal brushborder enzyme activity appear to be unique.
Despite the increased capacity of the small intestine to digest disaccharides after chronic treatment with GLP-2, no marked changes were observed in the glycemic responses to orally administered maltose. Similarly, glucose absorption alone was not affected after either chronic or acute administration of GLP-2. Assimilation of maltose across the intestine requires cleavage by maltase into two units of glucose, followed by absorption of the glucose across the enterocyte through the actions of both SGLT-1 and GLUT-2 (17, 40). Unexpectedly, the mRNA transcript levels for both of these facilitative glucose transporters were decreased in the jejunum of GLP-2-treated mice, and GLUT-2 transcript levels were also decreased in the ileum. Thus, despite the increased capacity of the small intestine to cleave maltose after GLP-2 treatment, this enhanced digestive activity may be uncoupled from subsequent absorption of the glucose product. Interestingly, mRNA transcript levels for both GLUT-2 and SGLT-1 are known to undergo adaptive increases in times of perceived glucose demand, such as in insulindeficient diabetes mellitus (4, 17), whereas basolateral glucose transport is increased by hyperglycemia (25). The results of the present study therefore suggest that, in the absence of an increased requirement for glucose, SGLT-1 and GLUT-2 expression does not undergo parallel adaptation with that of the disaccharidases. In recent experiments with rats, acute (4-h infusion) administration of GLP-2 increased the maximum veloc- relate to the present observations made in vivo remains to be determined; however, we did not observe changes in glucose absorption after a single injection of GLP-2. Finally, it must be noted that the normal glycemic profiles obtained for GLP-Z-treated mice in response to luminal glucose or maltose strongly suggest that the enteroinsular axis is not affected by chronic administration of GLP-2. Consistent with this suggestion, the levels of glucagon and insulin, as well as of the mRNA transcripts for the pancreatic hormones, were normal after treatment with GLP-2. In contrast to the lack of effect of GLP-2 on carbohydrate handling by the intestine, absorption of leucine and triolein by the duodenum was increased. This phenomenon was not observed after oral administration of these nutrients, presumably because of the ability of the stomach to control the rate of duodenal nutrient delivery. Whether GLP-2 has any effect on gastric emptying, as described for GLP-I (43), remains to be determined.
Leucine concentrations of GLP-2 in mice, fasting plasma levels in humans have been reported to be 600 pg/ml (30). Preliminary analyses in our laboratory have indicated that the plasma GLP-2 concentration in fasting mice is -320 pg/ml and that this is raised 150-fold 2 h after administration of 43.75 lug of GLP-2 (Brubaker, unpublished data). In the present studies, therefore, treatment of mice with 2.5 lug of GLP-2 was predicted to raise GLP-2 levels by approximately ninefold. It must be noted, however, that these values reflect the circulating levels of immunoreactive peptide only, and determinations of increments in biologically active GLP-2 levels await detailed studies on the metabolism of this peptide. In summary, the results of the present study demonstrate that administration of GLP-2 stimulates duodenal brush-border disaccharidase and peptidase activity in association with growth of the small intestine. These findings suggest that GLP-2 induction of small bowel growth results in proliferation of intestinal epithelium that appears to retain the functional capacity for norm .a1 nutrient absorpti .on in vivo. 
